Lipoprotein(a) levels in children with hypercholesterolemia.

Area of Science:

• Pediatrics
• Cardiology
• Genetics

Background:

• Lipoprotein(a) [Lp(a)] is a key genetic risk factor for cardiovascular disease (CVD).
• Extremely high Lp(a) levels can elevate low-density lipoprotein cholesterol (LDL-C) due to particle similarities.
• The role of Lp(a) in pediatric hypercholesterolemia is not well understood.

Purpose of the Study:

• To investigate the impact of Lp(a) on LDL-C in children with hypercholesterolemia.
• To determine the prevalence of elevated Lp(a) in pediatric hypercholesterolemia cohorts.
• To assess the contribution of Lp(a) to overall LDL-C levels in affected children.

Main Methods:

• Study included 1,418 children with hypercholesterolemia identified via screening.
• Participants were categorized into definite FH, possible FH, and definite non-FH groups.
• Analysis focused on Lp(a) levels and their correlation with LDL-C and Apolipoprotein B.

Main Results:

• Elevated Lp(a) (>30 mg/dL) was found in 25.1% of definite FH and 34.9% of possible FH cases.
• Lp(a) contributed significantly to LDL-C (10.3% of variability) and Apolipoprotein B levels.
• Even after Lp(a) adjustment, elevated LDL-C persisted in a majority of definite FH (88.4%) and a significant portion of possible FH (30.4%) children.

Conclusions:

• Approximately one in four children with FH and one in three with polygenic hypercholesterolemia exhibit elevated Lp(a).
• Elevated Lp(a) contributes to elevated LDL-C and Apolipoprotein B in these pediatric populations.
• Early identification and management of modifiable risk factors like elevated LDL-C and obesity are essential for these children.